Keywords: مقاومت به دست آورد; Culturable fecal indicator bacteria; Biodiversity; Antibiotic resistance; Acquired resistance; Ã-lactams; WWTP;
مقالات ISI مقاومت به دست آورد (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: مقاومت به دست آورد; NSCLC; Plasma genotyping; Liquid biopsy; Targeted therapy; EGFR; Acquired resistance;
Keywords: مقاومت به دست آورد; Acquired resistance; Androgen receptor; Androgens; Hormonal therapy; Primary resistance;
Keywords: مقاومت به دست آورد; Acquired resistance; EGFR mutation; Gefitinib; Autopsy; Molecular target therapy; T790M mutation;
Keywords: مقاومت به دست آورد; Ovarian cancer; Platinum-resistant; Platinum-sensitive; Innate resistance; Acquired resistance;
Keywords: مقاومت به دست آورد; Species diversity; Wildlife diseases; Amphibian declines; Acquired resistance; Density-dependent transmission
Keywords: مقاومت به دست آورد; Tumor microenvironment; Cancer therapy; Acquired resistance; Personalized medicine;
Keywords: مقاومت به دست آورد; Non-small cell lung cancer; EGFR mutation; Afatinib; Acquired resistance; T790M; Progression biopsy;
Keywords: مقاومت به دست آورد; Cancer therapy; Targeted therapy; Resistance mechanisms; Intrinsic resistance; Acquired resistance; Trastuzumab
Keywords: مقاومت به دست آورد; Advanced hepatocellular carcinoma (HCC); Epithelial-mesenchymal transitions (EMT) and mesenchymal-epithelial transitions (MET); Cancer stem cells (CSCs); Microenvironment; Acquired resistance;
Keywords: مقاومت به دست آورد; GIST; gastrointestinal stromal tumor; KIT; mast/stem cell growth factor receptor Kit; PDGFRA; platelet-derived growth factor receptor alpha; RTK; receptor tyrosine kinase; EGFR; epidermal growth factor receptor; PI3K; phosphatidylinositol 3-kinase; Akt; p
Keywords: مقاومت به دست آورد; Acquired resistance; Drug sensitivity; EGFR tyrosine kinase inhibitor; Non–small-cell lung cancer; Organ
Keywords: مقاومت به دست آورد; Acquired resistance; Gefitinib; EGFR-tyrosine kinase inhibitor; Non-small cell lung cancer; Post-progression survival (PPS); Failure togefitinib;
Keywords: مقاومت به دست آورد; EGFR-TKI; epidermal growth factor receptor tyrosine kinase inhibitor; MST; median survival time; HGF; hepatocyte growth factor; FISH; fluorescence in situ hybridization; PTEN; phosphatase and tensin homolog deleted from chromosome 10; PI3K; phosphoinositi
Keywords: مقاومت به دست آورد; EGFR; epidermal growth factor receptor; NSCLC; non-small cell lung cancer; TKI; tyrosine kinase inhibitor; WT; wild type; KRAS; Kirsten RNA associated rat sarcoma 2 virus gene; PTEN; phosphatase and tensin homolog; HGF; hepatocyte growth factor; IGF1R; in
Keywords: مقاومت به دست آورد; Acquired resistance; BCR-ABL1; Kinase domain mutation; Tyrosine kinase inhibitor; T315I
Keywords: مقاومت به دست آورد; EGFR; GM-CSF; IL-8; Head and neck squamous cell carcinoma; Survival; Acquired resistance; Serum protein signature; TIMP-1; Tyrosine kinase inhibitor; VEGF;
Keywords: مقاومت به دست آورد; EGFR-TKI; EGFR mutation; HGF; Acquired resistance; Intrinsic resistance
Use of erlotinib and thalidomide in advanced NSCLC patients with acquired resistance to erlotinib: A pilot study
Keywords: مقاومت به دست آورد; Non-small-cell lung cancer; Thalidomide; EGFR-TKI; Acquired resistance; Erlotinib;
Molecular mechanism of D816X mutation-induced c-Kit activation and -mediated inhibitor resistance in gastrointestinal stromal tumor
Keywords: مقاومت به دست آورد; c-Kit kinase; D816X mutation; Constitutive activation; Tyrosine kinase inhibitor; Acquired resistance; Gastrointestinal stromal tumor;
Clinical Implications of the T790M Mutation in Disease Characteristics and Treatment Response in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC)
Keywords: مقاومت به دست آورد; Acquired resistance; Chemotherapy; EGFR tyrosine kinase inhibitor; Progression-free survival; Targeted therapy;
Squamous Cell Carcinoma Transformation from EGFR-mutated Lung Adenocarcinoma: A Case Report and Literature Review
Keywords: مقاومت به دست آورد; Acquired resistance; Histologic transformation; Non-small-cell lung cancer; Osimertinib; T790M;
Clinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in 26 Patients With Advanced Non-Small Cell Lung Cancer
Keywords: مقاومت به دست آورد; PD-1; PD-L1; acquired resistance; non-small cell lung cancer; immunotherapy;
Clinical Factors Predicting Detection of T790M Mutation in Rebiopsy for EGFR-Mutant Non-small-cell Lung Cancer
Keywords: مقاومت به دست آورد; Acquired resistance; Disease progression; EGFR-TKI; Epidermal growth factor receptor; Predictive marker;
Oral recombinant methioninase (o-rMETase) is superior to injectable rMETase and overcomes acquired gemcitabine resistance in pancreatic cancer
Keywords: مقاومت به دست آورد; Pancreatic cancer; Acquired resistance; Methionine dependence; Gemcitabine; Oral administration; PDOX;
Cynanbungeigenin C and D, a pair of novel epimers from Cynanchum bungei, suppress hedgehog pathway-dependent medulloblastoma by blocking signaling at the level of Gli
Keywords: مقاومت به دست آورد; Hh pathway inhibitor; Gli inhibitor; Natural product; C21 steroid; Medulloblastoma; Acquired resistance;
Short communicationEmergence of EGFR G724S mutation in EGFR-mutant lung adenocarcinoma post progression on osimertinib
Keywords: مقاومت به دست آورد; EGFR; G724S; T790M; Acquired resistance; Osimertinib; Lung cancer;
Case reportSequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLC
Keywords: مقاومت به دست آورد; Osimertinib; EGFR; Lung cancer; Acquired resistance; Liquid biopsy;
Genomic Profiling of Circulating Tumor DNA in Relapsed EGFR-mutated Lung Adenocarcinoma Reveals an Acquired FGFR3-TACC3 Fusion
Keywords: مقاومت به دست آورد; Acquired resistance; ctDNA; EGFR mutation; FGFR3 fusion; Non-small-cell lung cancer;
Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non-Small-Cell Lung Cancer
Keywords: مقاومت به دست آورد; Acquired resistance; AKT; Combination therapy; EGFR mutant; ERK;
HSP70 expression in Biomphalaria glabrata snails exposed to cadmium
Keywords: مقاومت به دست آورد; Protein induction; Biomarker; Bioindicator; Mollusk; Acquired resistance;
Effect of dasatinib on EMT-mediated-mechanism of resistance against EGFR inhibitors in lung cancer cells
Keywords: مقاومت به دست آورد; Epithelial-mesenchymal transition; Acquired resistance; Dasatinib; Third- generation EGFR-TKI; Non-small cell lung cancer;
Original articleA phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib
Keywords: مقاومت به دست آورد; AE; adverse events; Afa; afatinib; AR; acquired resistance; AUC; area under curve; CR; complete response; CTCAE; Common Terminology Criteria for Adverse Events; CTP; clinical trial protocol; DLT; dose-limiting toxicity; ECOG; Eastern Cooperative Oncology
ReviewOptimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy
Keywords: مقاومت به دست آورد; Acquired resistance; Epidermal growth factor receptor mutation; Non-small cell lung cancer; Osimertinib; T790M; Tyrosine kinase inhibitor;
Polyphyllin VII increases sensitivity to gefitinib by modulating the elevation of P21 in acquired gefitinib resistant non-small cell lung cancer
Keywords: مقاومت به دست آورد; P21; Acquired resistance; NSCLC; Polyphyllin; Cell cycle;
Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells
Keywords: مقاومت به دست آورد; EGFR mutation; Immunotherapy; Acquired resistance; EGFR-TKIs; Epithelial to mesenchymal transition (EMT); Erlotinib;
Pharmacological synergism of 2,2-dichloroacetophenone and EGFR-TKi to overcome TKi-induced resistance in NSCLC cells
Keywords: مقاومت به دست آورد; Erlotinib (PubChem CID: 176870); Gefitinib (PubChem CID: 123631); Sodium dichloroacetate (PubChem CID: 517326); 2,2-dichloroacetophenone (PubChem CID: 72870); Synergism; Dichloroacetophenone; Dichloroacetate; EGFR; Apoptosis; Acquired resistance;
[11C]Erlotinib PET cannot detect acquired erlotinib resistance in NSCLC tumor xenografts in mice
Keywords: مقاومت به دست آورد; Non-small cell lung cancer; Epidermal growth factor receptor; Acquired resistance; T790M; MET amplification; [11C]erlotinib;
Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment
Keywords: مقاومت به دست آورد; PD-1; PD-L1; Checkpoint inhibitors; Primary resistance; Acquired resistance;
Antimicrobial susceptibility and MIC distribution of 41 drugs against clinical isolates from China and reference strains of nontuberculous mycobacteria
Keywords: مقاومت به دست آورد; Nontuberculous mycobacteria; Drug susceptibility; Minimum inhibitory concentration; Acquired resistance; Rapidly growing mycobacterium; Slowly growing mycobacterium;
Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib
Keywords: مقاومت به دست آورد; NSCLC; T790M; BRAF V600E; Acquired resistance; Targeted therapy;
Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells
Keywords: مقاومت به دست آورد; CRM1; chromosome region maintenance 1; EGFR; epidermal growth factor receptor; EMT; epithelial-mesenchymal transition; LMB; leptomycin B; MTT; 3-(4,5-dimetrylthiazol)-2,5-diphenyltetrazolium bromide; NSCLC; non-small cell lung cancer; TKIs; tyrosine kinas
Enhanced B-Raf-mediated NRF2 gene transcription and HATs-mediated NRF2 protein acetylation contributes to ABCC1-mediated chemoresistance and glutathione-mediated survival in acquired topoisomerase II poison-resistant cancer cells
Keywords: مقاومت به دست آورد; ABC; ATP-binding cassette; ABCC; The ABC subfamily C; ABCC1; ATP-binding cassette subfamily C member 1; AHR; aryl hydrocarbon receptor; AKR1C1; aldo-keto reductase family 1 member C1; AREs; antioxidant-responsive elements; B-Raf; B-Raf proto-oncogene, ser
Heterogeneity in Immune Marker Expression after Acquisition of Resistance to EGFR Kinase Inhibitors: Analysis of a Case with Small Cell Lung Cancer Transformation
Keywords: مقاومت به دست آورد; PD-L1; EGFR mutation; Acquired resistance; Gefitinib; Autopsy; Immune biomarkers;
A Phase 1/2 Trial of Ruxolitinib and Erlotinib in Patients with EGFR-Mutant Lung Adenocarcinomas with Acquired Resistance to Erlotinib
Keywords: مقاومت به دست آورد; EGFR; Acquired resistance; Ruxolitinib; Erlotinib; JAK; STAT;
Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench
Keywords: مقاومت به دست آورد; EGFR mutation; Acquired resistance; Molecular mechanisms; Drug-tolerant state; Microenvironment; Tumor heterogeneity;
Response and acquired resistance to crizotinib in Chinese patients with lung adenocarcinomas harboring MET Exon 14 splicing alternations
Keywords: مقاومت به دست آورد; Lung cancer; MET exon 14 splicing mutations; Circulating tumor DNA; Acquired resistance;
Neoadjuvant Oncogene-Targeted Therapy in Early Stage Non-Small-Cell Lung Cancer as a Strategy to Improve Clinical Outcome and Identify Early Mechanisms of Resistance
Keywords: مقاومت به دست آورد; Acquired resistance; ALK; Clinical trial; Crizotinib; EGFR; MET exon 14; Neoadjuvant treatment; NSCLC; ROS1;
The role and mechanism of autophagy in sorafenib targeted cancer therapy
Keywords: مقاومت به دست آورد; Sorafenib; Autophagy; Targeting kinase inhibitor; Acquired resistance;
Acquired Resistance to Crizotinib in NSCLC with METÂ Exon 14 Skipping
Keywords: مقاومت به دست آورد; NSCLC; MET exon 14 skipping; Acquired resistance; Targeted therapy;